Canopy Growth (CGC) Interest & Investment Income (2019 - 2026)
Canopy Growth (CGC) posted Interest & Investment Income of $4.4 million for Q4 2025, up 206.3% sequentially from $1.4 million in Q3 2025, and up 216.52% YoY from $1.4 million in Q4 2024.
Canopy Growth (CGC) Interest & Investment Income (2019 - 2026) Analysis & Trends
Canopy Growth has reported Interest & Investment Income for 7 years, with the latest figure at $4.4 million in Q4 2025.
- Quarterly Interest & Investment Income rose 216.52% year-over-year to $4.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.0 million (up 23.86% YoY) and the FY2026 annual result came in at $7.3 million, up 18.66% from the prior year.
- Interest & Investment Income grew to $4.4 million in Q4 2025 per CGC's latest filing, from $1.4 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $6.2 million in Q1 2023 and troughed at -$296842.8 in Q1 2022.
- A 5-year average of $2.6 million and a median of $1.9 million in 2023 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2023: Interest & Investment Income plunged 116.41% in 2022, then jumped 2183.21% in 2023.
- Over 5 years, Interest & Investment Income stood at $1.2 million in 2021, then soared by 315.55% to $5.2 million in 2022, then tumbled by 63.95% to $1.9 million in 2023, then fell by 25.76% to $1.4 million in 2024, then soared by 216.52% to $4.4 million in 2025.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $4.4 million, $1.4 million, and $762850.1 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 154.39 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 31.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 12.40 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Canopy Growth | 434.93 Mn | 187.92 Mn | 16.08 Mn | 2.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.34 Mn |
| Dec 31, 2025 | 4.40 Mn |
| Sep 30, 2025 | 1.44 Mn |
| Jun 30, 2025 | 762,850.11 |
| Dec 31, 2024 | 1.39 Mn |
| Sep 30, 2024 | 1.77 Mn |
| Jun 30, 2024 | 1.50 Mn |
| Mar 31, 2024 | 1.78 Mn |
| Dec 31, 2023 | 1.87 Mn |
| Sep 30, 2023 | 2.58 Mn |
| Jun 30, 2023 | 5.83 Mn |
| Mar 31, 2023 | 6.18 Mn |
| Dec 31, 2022 | 5.19 Mn |
| Sep 30, 2022 | 3.78 Mn |
| Jun 30, 2022 | 3.10 Mn |
| Mar 31, 2022 | -296,842.75 |
| Dec 31, 2021 | 1.25 Mn |
| Sep 30, 2021 | 2.19 Mn |
| Jun 30, 2021 | 2.15 Mn |
| Mar 31, 2021 | 1.81 Mn |